Cencora (COR) reported $321B in revenue for fiscal 2025, +9.3% year on year. That ranks #9 by revenue among 2853 SEC filers and #4 in Healthcare. Net income was $1.6B, a net margin of 0.5%. Revenue has grown 10.6% a year on average since 2011 ($78.7B then). The fiscal 2025 balance sheet shows $78.4B in total assets, $1.8B in cash and $7.6B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $321B | +9.3% | FY20252025-09-30 |
| Gross profitGrossProfit | $11.5B | +15.8% | FY20252025-09-30 |
| Operating incomeOperatingIncomeLoss | $2.6B | +20.8% | FY20252025-09-30 |
| Net incomeNetIncomeLoss | $1.6B | +3.0% | FY20252025-09-30 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $3.9B | +11.2% | FY20252025-09-30 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $668M | +37.1% | FY20252025-09-30 |
| Total assetsAssets | $78.4B | +13.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.9B | +742.2% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $1.8B | −45.6% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $7.6B | +27.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $78.4B | $1.6B | Open → |
| Q2 20262026-06-30 | $84.8B | $764M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 117 of 161 companies compared | 0.5% | |
| Operating marginRank 129 of 160 companies compared | 0.8% | |
| Cash as share of revenueRank 159 of 160 companies compared | 0.5% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Cencora, Inc.
- Ticker
- COR
- Exchange
- NYSE
- SIC classification
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- Fiscal year end
- 09-30
- CIK
- 0001140859
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-QFeb 4, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| UnitedHealth GroupUNH | $448B | $12.1B |
| McKessonMCK | $403B | $4.8B |
| CVS HealthCVS | $402B | $1.8B |
| CencoraCOR | $321B | $1.6B |
| Cigna GroupCI | $275B | $6.0B |
| Cardinal HealthCAH | $223B | $1.6B |
| Elevance HealthELV | $199B | $5.7B |
Cencora compared withAlphabetAmazonAppleBerkshire Hathaway
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Cencora — Key figures |url=https://companiesranked.com/en/company/cencora |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Cencora — Key figures. CompaniesRanked. https://companiesranked.com/en/company/cencoraBibTeX
@misc{companiesranked-en-company-cencora-2026,
author = {{CompaniesRanked}},
title = {{Cencora — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/cencora}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.